Twist Bioscience Corporation Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
Twist Bioscience Corporation (TWST) reported Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions of $2.62 million for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-17.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions · last filed 2025-11-17
- Twist Bioscience Corporation unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2025 was $2.62M, a 21.97% decline from fiscal 2024.
- Twist Bioscience Corporation unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2024 was $3.35M, a 33.49% decline from fiscal 2023.
- Twist Bioscience Corporation unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2023 was $5.04M, a 0.77% decline from fiscal 2022.
- Twist Bioscience Corporation unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2022 was $5.08M, a 85.68% increase from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month |
|---|---|
| 2025-09-30 | $2.62M 10-K · filed 2025-11-17 |
| 2024-09-30 | $3.35M 10-K · filed 2025-11-17 |
| 2023-09-30 | $5.04M 10-K · filed 2025-11-17 |
| 2022-09-30 | $5.08M 10-K · filed 2024-11-18 |
| 2021-09-30 | $2.74M 10-K · filed 2023-11-21 |
| 2020-09-30 | $1.41M 10-K/A · filed 2023-06-05 |
| 2019-09-30 | $1.04M 10-K · filed 2021-11-23 |
| 2018-09-30 | $624.00K 10-K · filed 2020-11-27 |
| 2017-09-30 | $562.00K 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |